Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Biomet announces IPO plans
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
A group of private PE players including the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG acquired Biomet for $11.4 billion in 2007, placing medtech veteran Jeffrey Binder at the helm. Read more
2. FDA rejects ANGO distro partner; 510k
Medical device maker AngioDynamics announced progress in its regulatory efforts, landing FDA clearance for the latest in its BioFlo vascular access line and taking over 510(k) efforts for Medcomp’s Celerity tip location system.
AngioDynamics touted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter, now the 3rd in the company’s portfolio of FDA-cleared BioFlo products. AngioDynamics expects commercial launch during its 4th quarter of 2014, according to a company statement. Read more
1. Europe spikes Edwards Lifesciences’ TAVI patent in war with Medtronic
Medtech titan Medtronic landed a major win against arch-rival Edwards Lifesciences when the European Patent Office revoked an Edwards patent at the heart of a contentious infringement lawsuit.
The EPO decision stymies Edwards’ efforts to keep Medtronic’s CoreValve transcatheter aortic valve implantation system off the market, but doesn’t affect Edwards’ own sales. The ruling is open for appeal and Edwards plans to pursue one. Read more
